Rimonabant (Acomplia): a novel adjunctive treatment for obesity
Authors
Abstract
Rimonabant is the first selective cannabinoid‐1 receptor inhibitor for use in the treatment of obesity. In this article Professor Barnett describes its novel mode of action and the results of clinical trials of its efficacy and safety. Copyright © 2007 Wiley Interface Ltd
Digital Object Identifier (DOI)
10.1002/psb.9 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
